Systematic Review and Expert Consensus on the Use of Long-acting Monoclonal Antibodies for Prevention of Respiratory Syncytial Virus Disease: ARMADA (Advancing RSV Management And Disease Awareness) Taskforce - Takeaways - MDSpire

Systematic Review and Expert Consensus on the Use of Long-acting Monoclonal Antibodies for Prevention of Respiratory Syncytial Virus Disease: ARMADA (Advancing RSV Management And Disease Awareness) Taskforce

  • By

  • Paolo Manzoni

  • Eugenio Baraldi

  • Fabio Midulla

  • Olivier Claris

  • Sandro Dessardo

  • Terho Heikkinen

  • Richard Thwaites

  • Bosco Paes

  • Xavier Carbonell-Estrany

  • Dmytro Dobryanskyy

  • Merih Cetinkaya

  • Adel S Al Harbi

  • Ji-Man Kang

  • Anne Goh Eng Neo

  • Hsin Chi

  • Guilherme Sant’Anna

  • Mónica Villa Guillén

  • Gonzalo Luis Mariani

  • Marco Aurelio Palazzi Safadi

  • Soledad Urzua

  • Heather J Zar

  • Pierre Goussard

  • Barry Rodgers-Gray

  • Nicola Waghorne

  • Manuel Sanchez Luna

  • July 2, 2025

  • 0 min

Share

  • 1

    The ARMADA Taskforce recommends long-acting monoclonal antibodies (LAmAbs) for infants under 8 months without maternal RSV vaccination.

  • 2

    Preterm infants under 12 months and children under 24 months with high-risk conditions should also receive LAmAbs for RSV prevention.

  • 3

    Seasonal administration of LAmAbs is advised, with local decisions for year-round use in RSV-endemic countries.

  • 4

    The Taskforce emphasizes the need for affordable access to LAmAbs, particularly in low- and middle-income countries.

  • 5

    Wider implementation of LAmAbs is crucial to reduce the global burden of severe RSV disease in infants and young children.

Original Source(s)

Systematic Review and Expert Consensus on the Use of Long-acting Monoclonal Antibodies for Prevention of Respiratory Syncytial Virus Disease: ARMADA (Advancing RSV Management And Disease Awareness) Taskforce

  • by Paolo Manzoni, Eugenio Baraldi, Fabio Midulla, Olivier Claris, Sandro Dessardo, Terho Heikkinen, Richard Thwaites, Bosco Paes, Xavier Carbonell-Estrany, Dmytro Dobryanskyy, Merih Cetinkaya, Adel S Al Harbi, Ji-Man Kang, Anne Goh Eng Neo, Hsin Chi, Guilherme Sant’Anna, Mónica Villa Guillén, Gonzalo Luis Mariani, Marco Aurelio Palazzi Safadi, Soledad Urzua, Heather J Zar, Pierre Goussard, Barry Rodgers-Gray, Nicola Waghorne, Manuel Sanchez Luna

  • July 2, 2025

Related Content

Medical Oddities: Something Viral is Lurking in the Dust

Everyday things like yawns, tea, dust, and kimchi suddenly look medically important.

The Flu Vaccine Face-Off Ends in a Draw

Pragmatic cluster randomized crossover study found no statistically significant difference in laboratory-confirmed influenza during the 2023-2024 season

Senate Report Details Early Myocarditis Signals After COVID-19 Vaccination

Investigative report cites internal communications, VAERS data, and CDC case reviews describing myocarditis and pericarditis reports in adolescents and young adults after mRNA COVID-19 vaccination.